



Grŵp Strategaeth Meddyginiaethau Cymru Gyfan  
All Wales Medicines Strategy Group



# Annual Report: 2024-2025

*Improving the health and well-being of people  
in Wales by enabling patients to get the best  
outcomes from their medicines*



*This document is available in Welsh  
Mae'r ddogfen hon ar gael yn Gymraeg*

<b>Foreword</b>	03	<b>Medicines optimisation</b>	24
Chair's welcome	03	Prescribing guidance and resources	24
AWTTC Directors' summary	05	Acknowledgements	26
Welsh Government statement	07		
<b>About us</b>	09	<b>Prescribing monitoring and analysis</b>	27
Profile of AWMSG	09	National Prescribing Indicators	27
2024-2025 in numbers	09		
<b>Working in partnership</b>	10	<b>Medicines access</b>	28
Our partners and how they get involved	10	Horizon scanning	28
What we have achieved together	13	Routes of access	30
Engagement	15	Implementation	31
<b>News</b>	19	<b>Research and publications</b>	33
Getting the best outcomes from medicines	19	Activity during 2024-2025	33
Enabling access to medicines	20		
Medicines-related safety	22		
Optimising value	23		

# Foreword

## Chair's welcome

It is with great pleasure that I present the Annual Report of the All Wales Medicines Strategy Group (AWMSG) for this reporting year. The past year has brought both progress and challenge, underscoring the continued importance of our work in supporting the safe, effective, and equitable use of medicines across NHS Wales.



**The past year has brought both progress and challenge, underscoring the continued importance of our work in supporting the safe, effective, and equitable use of medicines across NHS Wales.**



AWMSG plays a vital role in ensuring that patients and families in Wales have timely access to clinically effective and cost-effective medicines. We work in close collaboration with healthcare professionals, industry partners, and patients and the public to provide evidence-based medicine assessment and develop national prescribing guidance and resources. This year, we have maintained our focus on delivering meaningful outcomes for the people of Wales by embracing innovation, strengthening clinical engagement, and embedding the principles of value-based healthcare in everything we do.

Highlights of this year's work include the recommendation of several medicines that will make a real difference to patient care and quality of life. We have continued to refine and streamline our AWMSG medicine assessment processes, ensuring efficiency while upholding the highest standards of transparency and rigour. The One Wales Medicines process was recognised at the Moondance Cancer Awards, and I am very proud of the work AWTTTC do to support medicines access in Wales.



**AWMSG plays a vital role in ensuring that patients and families in Wales have timely access to clinically effective and cost-effective medicines.**



Through medicines optimisation we also support prescribers to make informed decisions aligned with national priorities and best practice guidance. I would like to acknowledge the hard work that has been undertaken this year to review the National Prescribing Indicators for April 2025 to March 2028 and I look forward to receiving updates at future AWMSG meetings. I would also like to congratulate staff from AWTTTC and Public Health Wales who

# Foreword

## Chair's welcome

received the Sustainability in Healthcare award at the Welsh Pharmacy Awards for their work on reducing the carbon footprint associated with inhalers in line with the national decarbonisation strategy.

None of this would be possible without the dedication and expertise of AWTTTC staff, our committee members, clinical experts, patient and public representatives, and wider stakeholders. Their commitment to improving medicines use across Wales remains the cornerstone of AWMSG's success.

Looking ahead, we remain committed to responding to emerging challenges in the healthcare landscape, from evolving therapeutic areas to the financial pressures facing the NHS. AWMSG will continue to champion the responsible use of medicines and strive for improvements that benefit all communities in Wales.

Thank you for your continued support and engagement.

“  
**AWMSG will continue to champion the responsible use of medicines and strive for improvements that benefit all communities in Wales.**  
”



**Professor Iolo Doull**  
Chair  
AWMSG

A handwritten signature in blue ink, appearing to read 'Iolo Doull'.



Wales, in common with other devolved administrations, faces considerable clinical, financial and social pressures. The need for timely access to clinically and cost-effective medications has never been greater.

The All Wales Therapeutics and Toxicology Centre (AWTTC) is a multidisciplinary team of clinicians, pharmacists, scientists, health economists, information technology specialists and administrators. We provide understanding in medicines access, medicines optimisation, medicine safety and toxicology to Welsh Government, NHS Wales, Health Boards in Wales and individual healthcare professionals.

AWTTC supports the mission of AWMSG by providing a scientific, technical, and administrative secretariate to AWMSG and its associated subcommittees. We work closely with AWMSG members to ensure Welsh Government and NHS Wales have high quality intelligence reviewed by independent experts to aid their decision making.

We welcomed the Cabinet Secretary for Health and Social Care remit letter of January 2025, which identified five key priorities for AWMSG to deliver over the next three years.

Our team is working closely with AWMSG to deliver on these challenges, promote environmental sustainability, and eliminate health inequalities across Wales.

AWTTC is collaborating with our UK-wide partners to support the new Innovative Licensing and Access Pathway (ILAP), a world-first initiative that integrates medicines regulation and health technology appraisal to deliver transformative medicines and medicine-devices timely and efficiently to the devolved National Health Services.

**We will continue to apply our professional expertise and to develop our reputation in data science and data analytics...**

“

**Our expertise is founded on our research excellence.**

”

AWTTC is responding to the opportunity afforded by the Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG) Investment Programme by enhancing our capabilities in horizon scanning, medicines ecosystem, data acquisition and implementation. Funding has been secured until 2028-29 to meet a number of key objectives that will drive innovation in the delivery of HTA, support implementation and improve data collection and analytics. Achieving this will allow us the resolution to measure effects of changes and plan further adjustments to optimise the impact of medicines in Wales.

Our expertise is founded on our research excellence. We collaborate closely with our academic and health service colleagues to explore clinically relevant topics and develop

our in-house capabilities. This year we have published seven peer-reviewed articles in the clinical and scientific literature, presented at international conferences and delivered invited presentations across the UK.

We will continue to apply our professional expertise and to develop our reputation in data science and data analytics to support our AWMMSG colleagues in delivering world-class medicines access and medicines management to the people of Wales. Finally, we would like to thank all the fantastic staff at AWTTCC for their determination, vision and expertise for delivering such a high quality work programme over the last 12 months.



**AWTTC supports the mission of AWMMSG by providing a scientific, technical, and administrative secretariate...**



**Dr Andrew Champion**  
Programme Director  
AWTTC



**Professor James Coulson**  
Clinical Director  
AWTTC



Medicines play a crucial role in improving the quality and increasing the length of many people's lives. Advances in treatment are offering greater than ever opportunity to radically change the course of disease and in some cases, reverse or cure conditions for which previous treatments offered little or no chance of meaningful improvement.

In Wales, we can be proud of the steps which have been taken to ensure people have prompt access to these clinically effective medicines regardless of where in Wales they live, and at a cost which represents value for money for the NHS.

The All Wales Medicines Strategy Group (AWMSG) plays a crucial leadership role assessing, guiding and monitoring the availability and use of the medicines we make routinely available in the NHS. It is therefore pleasing to see that the significant improvements made to the timeliness of access to innovative medicines since the introduction of the Welsh Government's New Treatment Fund in 2017, have again been maintained and the number of medicines appraised and supported by the fund has increased since AWMSG's last annual report.



**I am grateful to the Chair and members of AWMSG, and to members of each of AWMSG's subgroups, for the time and expertise they give in contributing to the committee's work...**



Whilst health technology assessment remains the predominant route by which medicines are approved for use in Wales, for some people including those with rarer diseases, repurposing medicines provides for a novel, evidence-based approach to treatment. The increasing use of the One Wales route to access and AWMSG's increasingly important role in scrutinising One Wales decisions highlighted by this year's report, demonstrates our collective, ongoing

commitment to finding creative ways to improve access to treatment and certainty for patients and clinicians alike.

As access to medicines increases so does the cost to the NHS. The NHS in Wales invests more than £1bn every year on medicines with the level of investment in 2024/25 higher than it has ever been. This makes it imperative that medicines are used effectively in ways which maximise their benefits and minimise their risks. I welcome the importance AWMSG has placed in the last year on developing comprehensive medicines optimisation guidance and prescribing resources to support clinical teams to improve how medicines are prescribed and used. The renewed focus on medicines optimisation including in high impact areas like the use of antipsychotics in dementia, tackling antimicrobial resistance and medicines shortages, will lead to positive improvements in the safe and effective use of medicines.

Once again, at a national level significant improvement has been made against AWMSG's national prescribing indicators. However, underlying the

overall improvement there is considerable variation between health boards, clusters and practices. We know the benefits of medicines are not necessarily felt equally and the distribution of good prescribing may benefit some people more than others. The improvements highlighted in this report provide a foundation for further positive progress to be made, but it will be of critical



**The All Wales Medicines Strategy Group (AWMSG) plays a crucial leadership role assessing, guiding and monitoring the availability and use of the medicines we make routinely available in the NHS.**



importance that AWMSG place even greater emphasis on measuring outcomes and tackling persistent inequalities in health by promoting equitable access to and prescribing of medicines for everyone in Wales in future years.

I am grateful to the Chair and members of AWMSG, and to members of each of AWMSG's subgroups, for the time and expertise they give in contributing to the committee's work, and to the work of staff of the All Wales Therapeutics and Toxicology Centre without whose support AWMSG would be unable to drive the continuous improvement in the safe, efficacious and cost effective use of medicines so evident in this annual report.

**Andrew Evans OBE FRPharmS**  
Chief Pharmaceutical Officer  
Welsh Government



Llywodraeth Cymru  
Welsh Government



# About us

## Profile of AWMSG

**Our vision for Wales – “To improve the health and well-being of people in Wales by enabling patients to get the best outcomes from their medicines”**

**Name:** All Wales Medicines Strategy Group (AWMSG)

**Chair:** Professor Iolo Doull

**Established:** 2002

**Role:** To advise Welsh Government on strategic developments in prescribing as outlined in the [AWMSG Strategy for Wales: 2024-2029](#).

**Members:** Includes doctors, nurses, pharmacists and other healthcare workers who can prescribe medicines, academics, health economists, a pharmaceutical industry representative, lay members and an NHS Director of Finance. See [Our Committees](#) on the AWTTTC website for lists of individual members.

**Accreditation:** The National Institute for Health and Care Excellence (NICE) accredited the AWMSG’s health technology assessment process as a mark of quality between 2011 and 2024 before closing its accreditation programme in July 2024.

### Advisory groups and subgroups:

- The All Wales Prescribing Advisory Group (AWPAG)
- The AWMSG Scrutiny Panel
- The AWMSG Steering Committee
- The Licensed One Wales Medicines Assessment Group (LOWMAG) which replaced the New Medicines Group (NMG)
- The One Wales Medicines Assessment Group (OWMAG)
- The Commercial Arrangement Scheme Wales Group (CASWG)

For more information see [Our Committees](#) on the AWTTTC website.

**Organisational:** The AWMSG Steering Committee oversees and guides strategic initiatives, and the All Wales Therapeutics and Toxicology Centre (AWTTTC) provides clinical, scientific, analytical and administrative support.

**Meetings:** 10 meetings were held in 2024–2025. Meetings are open to the public. The [minutes of previous meetings and dates of future ones](#) are on the AWTTTC website.

### More information:

[awttc.nhs.wales](http://awttc.nhs.wales) (English website)  
[cttcg.gig.cymru](http://cttcg.gig.cymru) (Welsh website)  
[@AWTTTCcomms](#) (English X account)  
[@AWTTTCcymraeg](#) (Welsh X account)  
[LinkedIn](#) (English and Welsh)

## 2024–2025 in numbers



10 meetings held



5 medicines appraised by AWMSG




4 One Wales recommendations + 7 One Wales reviews



8 medicines optimisation publications




77 medicines on the New Treatment Fund




14 National Prescribing Indicators monitored

## Our partners and how they get involved

We work with patients and the public, healthcare professionals and representatives of the pharmaceutical industry, as well as Welsh Government and relevant UK organisations, to issue recommendations on medicines and guidance on optimising medicines use.



Our three key partners are: patients and the public; healthcare professionals; and the pharmaceutical industry. They are embedded into all aspects of our work and play a vital role in achieving our shared goals. There are many ways in which they can get involved in our work. Here are some examples.



### Patients and the public

- During our assessment of medicines, [we ask patients and the public for their views](#) about what it's like to live with their health condition and about any medicines they are, or were, taking for it. We consider these views when we make our recommendation to Welsh Government. [Medicine assessments currently in progress](#) are listed on the AWTTTC website.
- We produce resources to support the safe and best use of medicines in NHS

Wales. We ask patients and the public to [comment on every medicines resource](#) produced. We consider and address every response before the resource is finalised, endorsed and published. Current [open consultations](#) are listed on the AWTTTC website.

- [Our lay members](#) are members of the general public and are full voting members. They give an independent view and highlight what matters to patients, and their families and carers, to help inform decisions about new medicines and medicines resources.
- [Patient and Public Interest Group \(PAPIG\) meetings](#) are held four times a year and are supported by AWTTTC. They are an opportunity for patients and the public to hear about our work, and find out how they can [get involved](#).



## Healthcare professionals

- Our committee members bring together a wide variety of specialist knowledge, including those working in a range of healthcare professions across all areas of Wales. We encourage healthcare professionals to [contact us](#) if they are interested in [becoming a committee member](#).
- Healthcare professionals working in Wales can [propose a medicines optimisation resource](#) to be considered through our endorsement process, which includes open consultation via the AWTTTC website.
- Healthcare professionals are also invited to identify when an AWMSG assessment is required for a medicine. They may complete a [medicines request form for healthcare professionals](#) or email AWTTTC at [awttc@wales.nhs.uk](mailto:awttc@wales.nhs.uk).
- Any healthcare professional working with patients could have a significant role in [providing expert advice](#) to us. For example, we ask clinical experts to contribute to the AWMSG medicines assessment process, and to attend the Licensed One Wales Medicines Assessment Group (LOWMAG) and the One Wales Medicines Assessment Group (OWMAG) meetings to contribute to discussions. We also ask healthcare professionals to comment on the prescribing guidance and medicines optimisation resources we produce. The [AWMSG assessment work plan](#) and the current [open consultations](#) are listed on the AWTTTC website.
- AWTTTC host [Best Practice Days](#) in which healthcare professionals share best practice initiatives related to medicines optimisation. AWTTTC also host [Learning at Lunch](#) sessions – a series of one-hour online events covering therapeutic areas, national prescribing news and updates in clinical practice.





## Pharmaceutical industry

- AWTTTC's Industry Forum gives an opportunity for representatives from the pharmaceutical industry to meet regularly with AWTTTC to talk about issues relating to medicines access in Wales.
- AWTTTC's [horizon scanning](#) team gathers information on new medicines, indications (the conditions they treat) and new formulations in the pharmaceutical pipeline. [UK PharmaScan](#) is the team's primary source of information and we encourage all companies to engage with UK PharmaScan.
- The [Commercial Medicines Access Team](#) support and monitor the implementation of medicines recommended by AWMSG or the National Institute for Health and Care Excellence (NICE) when the medicine is associated with a commercial




arrangement with NHS Wales. Early engagement from the pharmaceutical industry enables the team to make sure that patients have timely access to medicines and that NHS Wales gets value for money.

- Companies are encouraged to get in touch as early as possible to tell us about pipeline medicines and share information to support with planning and implementation of medicines on the NICE work programme. In the absence of NICE advice, companies can [submit a medicine for consideration by the AWMSG Scrutiny Panel](#). The AWMSG Scrutiny Panel will decide if a medicine meets the AWMSG criteria for assessment by LOWMAG or OWMAG.
- Pharmaceutical companies can take part in consultations for any medicines optimisation resources that are in development. Every response is considered before the resource is finalised, endorsed and published. Current [open consultations](#) are listed on the AWTTTC website.

# What we have achieved together

## Patients and the public

 **4** PAPIG meetings

  
**18 speakers**

  
**95 attendees**

  
**13 medicines-related topics covered in depth**

 **10** medicines assessments

  
**19 submissions from patients and the public**

 **8** medicines optimisation consultations

  
**11 responses from patients and the public**

## Pharmaceutical industry

 **4** AWTTTC Industry Forum meetings

  
**2** presentations to the Ethical Medicines Industry Group (EMIG)

  
**1** presentation to the Association of the British Pharmaceutical Industry (ABPI) Board

  
**8** medicines optimisation consultations

  
**7** responses from pharmaceutical industry

# What we have achieved together



## Healthcare professionals

Healthcare professionals on our committees

20

AWMSG

9


NMG

24

AWPAG

18

OWMAG




8

medicines optimisation consultations

.....


88

responses from healthcare professionals




22

clinical experts involved in medicines assessments



1 Best Practice Day

.....



120 attendees



3

Learning at Lunch sessions

.....



479 attendees



9 clinical experts

+



14 expert groups

involved in developing medicines optimisation resources

The [AWTTC website](#) and social media are important ways we communicate with our partners; spreading the word about what we do.



67k separate visits



34k separate users



495k page views



81.5k X posts



289 LinkedIn followers

On our behalf, AWTTC organise and take part in key events to educate, exchange ideas, hear about personal experiences, network and spread awareness about what we do. Some events from the past year are listed below.



## Events from April 2024 to March 2025


### April 2024

- The [new AWMSG Five-Year Strategy was launched](#), setting out our ambitions and goals for 2024–2029. AWTTC worked closely with AWMSG to develop [the Strategy](#), after engagement with a wide range of partner organisations to ensure that it aligns to the priorities of NHS Wales, Welsh Government and the people of Wales.

### May 2024

- AWTTC's [Learning at Lunch](#) training session for healthcare professionals covered how to work together to

optimise antipsychotic use for people living with dementia, resources for the safe management of medicines within care homes, as well as a rapid therapeutics update.



- AWTTC staff gave [three talks and four poster presentations at the 44<sup>th</sup> Congress of European Association of the Poison Centres and Clinical Toxicologists \(EAPCCT\)](#). Topics included: intentional paracetamol ingestions in children; accidental intravascular administration of wound cleaning solutions; and exposures to Valerian herbal products.
- At the [Patient and Public Interest Group \(PAPIG\)](#) meeting senior scientists and consultant pharmacists gave presentations or led open discussions on

allergies to penicillin and what we can do to tackle antibiotic resistance. Updates were given on some in-development patient information leaflets, the Yellow Card Centre Wales, and the medicines access process.

- A [poster presented at the Prescribing and Research in Medicines Management \(PRIMM\) 34<sup>th</sup> Annual Scientific Meeting](#) about AW TTC's development of easy read formats of patient information leaflets in Wales was well received.
- [AW TTC hosted another successful Individual Patient Funding Request \(IPFR\) workshop](#). The annual workshop was well attended and provided training for IPFR panel members, health board colleagues involved in the delivery of the IPFR process, and clinicians with an interest in learning more about IPFR.



## June 2024

- AW TTC staff attended and presented [three posters at the Health Technology Assessment International \(HTAi\) Annual Meeting](#) in Seville with over 900 HTA professionals from over 60 countries in attendance. Poster topics included: NHS Wales as the first UK nation to approve use of dostarlimab for treatment of rectal cancer; off label rituximab as a first-line treatment for generalised myasthenia gravis; and modification of the AWMSG appraisal process.



- [AW TTC collaborated with the Wales Cancer Network](#) to develop more effective and 'Once for Wales' horizon scanning for cancer medicines. The team presented their work at the Systemic

Anti-Cancer Therapies (SACT) and Acute Oncology Service (AOS) Education Event in Llandudno, stimulating a lot of positive discussion with delegates.

## July 2024

- This year's [Best Practice Day](#) focused on medicines adherence. The event was opened by the Chief Pharmaceutical Officer for Wales, followed by talks from healthcare professionals and health psychologists in the morning, and interactive breakout sessions in the afternoon, alongside plenty of opportunities for colleagues from across Wales to network and catch up.



- [AWTTC staff presented a poster at the British Geriatric Society Spring Meeting](#) about identifying potential safety risks associated with the use of monitored dosage systems. The work was a collaboration between the UK National Poisons Information Service (NPIS), Swansea Bay University Health Board and AWTTC following discussion at the Best Practice Day in 2023.
- The [Yellow Card Centre Wales Annual Medicine Safety Day](#) was a great success, and a day of collaboration and learning. The event marked 60 years since the first Yellow Card was received in 1964.



## August 2024

- [Staff from AWTTC spent a week engaging with the public at the National Eisteddfod in Pontypridd.](#) They met many people and told them about our work in supporting the best and safe use of medicines, and explained how members of the public, patients, patient support groups, carers and healthcare professionals can get involved.



## September 2024

- Another interesting and informative [Patient and Public Interest Group \(PAPIG\)](#) meeting was held in September, with presentations including 'Unveiling

medication safety trends' and 'Medicines Safety Week and World Patient Safety Day - raising awareness on medication safety'.

- [Yellow Card Centre \(YCC\) Wales](#) joined AWTTC at the Royal Pharmaceutical Society Wales Conference to discuss the work of AWTTC and YCC Wales with delegates.



## October 2024

- Another popular [Learning at Lunch](#) session was held in October, and included a rapid therapeutics update, and presentations about oral morphine equivalence use in National Prescribing Indicators and the All Wales Adult Asthma Management and Prescribing Guidelines.

- [AWTTC staff gave a talk at the Royal College of Emergency Medicine Annual Scientific Conference](#) about the nature, frequency and severity of sodium azide-related enquires received by the National Poisons Information Service (NPIS) Cardiff unit, and the concern about the use of this chemical in deliberate self-harm.

## November 2024

- The last [PAPIG meeting](#) of 2024 saw a record number of attendees. Presentations focused on the Your Medicines, Your Health campaign, how health psychology can help support medicine adherence, and KidzMedz Cymru on teaching children how to safely swallow pills.
- [AWTTC's Senior staff visited the Rookwood radio station at Llandough Hospital](#) to spread the word about AWTTC to patients and staff. They were [interviewed by radio presenter Wesley Pritchard](#) and talked about the work of AWTTC and how listeners could get involved.

## February 2025

- The first [Learning at Lunch](#) session of 2025, provided the latest news about the National Prescribing Indicators, and a presentation of the AWMSG Good Practice Guide for back-up antibiotic prescribing.



## March 2025

- At the March [PAPIG meeting](#) there were two presentations: an update on the new AWMSG medicines assessment process, and a talk about interventions not usually available on the NHS – including what they are and under what circumstances they may be offered.

- The AWTTC Programme Director, [Dr Andrew Champion](#), was invited to speak at the [NICE 2025 annual conference](#) as part of the 'Driving creative solutions in HTA' session. Dr Champion spoke about the new medicines access process in Wales which was developed by AWTTC on behalf of AWMSG. He also participated in a question-and-answer session with fellow speakers.



# Getting the best outcomes from medicines

**AWMSG's five-year strategy for 2024-2029** defines four broad ambitions that members want our strategy to focus on: getting the best outcomes from medicines; enabling access to medicines; medicines-related safety; and optimising value. We've used these four ambitions to categorise some notable news stories of the past year.



One of our ambitions is to help people in Wales have the best opportunity to realise the intended benefits of the medicines they are prescribed, and the patient and

their prescriber should be supported in making that a reality. Where appropriate, this should include de-prescribing of medication when risk outweighs the benefit. Over the past year, we have worked with AWTTTC and our partners on a range of projects that have helped to realise this ambition.

## Common Ailments Service formulary updated

The [Common Ailments Service formulary](#) aims to improve patient access to consistent, evidence-based advice for the management of over 25 common ailments. In 2024-2025 the formulary was updated with a new monograph for 'Urinary tract infection in women and transgender males who have not undergone sex reassignment surgery' and minor updates made to many of the existing monographs.

**All Wales Common Ailments Service Formulary**  
August 2023

**1.4 Overview of treatment**  
Patients with acute vulvitis should be offered a 12-week course of a first line treatment option to be applied once daily in the evening initially. Frequency can be reduced if skin irritation occurs.

**Mild to moderate acne**  
A combined topical benzoyl peroxide (3% or 5%) and topical clindamycin (1%) preparation (i.e. Duac Once Daily gel). If Duac Once Daily gel is not suitable, consider referral to the GP for treatment with a topical clindamycin/retinoid combination preparation (e.g. Treclin®) or a topical benzoyl peroxide/salicylic acid combination preparation (e.g. Epiduo®).

Medication	1st line	2nd line
Generic name	Benzoyl peroxide (3% or 5%) with clindamycin (1%) gel (Duac Once Daily gel)	Benzoyl peroxide 5% gel
Legal class	OTC (supply via PCD)	P (Supply via PCD for an individual who is pregnant/breastfeeding)
Pack size	30 g, 60 g	30 g
Maximum number of packs to supply per consultation	1st 2, 2nd 2	2
Maximum number of consultations per episode†	2nd 1, 1st 1	1

## All Wales guidance for penicillin allergy de-labelling published

About 10% of patients admitted to hospital are labelled as penicillin allergic, but most of them have not experienced an allergic reaction. Penicillin allergy de-labelling is a key initiative to improve antibiotic prescribing and antimicrobial stewardship. The aim of the [All Wales guidance](#) is to guide best practice on the identification and removal of penicillin allergy labels in adults who have not experienced a true hypersensitivity reaction. The guidance is intended for use in patients reporting a penicillin allergy in secondary care settings in NHS Wales.

**All Wales guidance for penicillin allergy de-labelling in adults in secondary care**

Item	Yes	No
1. Do you work on one case register?	1	0
2. Do you have a penicillin allergy?	1	0
3. Do you have a penicillin allergy?	1	0
4. Do you have a penicillin allergy?	1	0
5. Do you have a penicillin allergy?	1	0
6. Do you have a penicillin allergy?	1	0
7. Do you have a penicillin allergy?	1	0
8. Do you have a penicillin allergy?	1	0
9. Do you have a penicillin allergy?	1	0
10. Do you have a penicillin allergy?	1	0
11. Do you have a penicillin allergy?	1	0
12. Do you have a penicillin allergy?	1	0
13. Do you have a penicillin allergy?	1	0
14. Do you have a penicillin allergy?	1	0
15. Do you have a penicillin allergy?	1	0
16. Do you have a penicillin allergy?	1	0
17. Do you have a penicillin allergy?	1	0
18. Do you have a penicillin allergy?	1	0
19. Do you have a penicillin allergy?	1	0
20. Do you have a penicillin allergy?	1	0
21. Do you have a penicillin allergy?	1	0
22. Do you have a penicillin allergy?	1	0
23. Do you have a penicillin allergy?	1	0
24. Do you have a penicillin allergy?	1	0
25. Do you have a penicillin allergy?	1	0
26. Do you have a penicillin allergy?	1	0
27. Do you have a penicillin allergy?	1	0
28. Do you have a penicillin allergy?	1	0
29. Do you have a penicillin allergy?	1	0
30. Do you have a penicillin allergy?	1	0



**We have an ambition to enable access to the right medicines at the right time for people in Wales. Medicines that are clinically and cost-effective are**

**required to be made available as an option to every person who needs treatment. Decisions on the availability of medicines should be made on a 'once for Wales' basis, whenever appropriate, to avoid duplication of effort across the service. During 2024-2025, we worked with AWTTTC on a range of projects to help achieve this ambition.**

## AWTTTC secures £3.3 million in funding

AWTTTC has secured funding of £3.3 million over five years (2024-2028) from the Voluntary Scheme for Medicines Pricing Access and Growth (VPAG) Investment Programme. The aim is to enable patients to access the latest treatments more consistently, to strengthen the UK's global competitiveness in advanced healthcare, technology, clinical research and promote better patient outcomes for a healthier population. AWTTTC is focused on four key areas: horizon scanning and financial

forecasting, data capture, medicines access, and implementation of new medicines.


## A new era for the Innovative Licensing and Access Pathway (ILAP)

ILAP is entering a new era that is focused on getting the most transformative new medicines to patients in the NHS quickly, by providing a single integrated platform for sustained collaborative working between the developer, the regulator, the NHS, and the UK health technology assessment bodies, AWTTTC, the National Institute for Health and Care Excellence and the Scottish Medicines Consortium. The partners have made key enhancements to the pathway this year and continued to engage with the life sciences sector to ensure a clearer, more streamlined and joined-up process.

## Updated AWMSG medicine assessment process launched

After a comprehensive review, a number of [changes to the AWMSG process for the assessment of medicines](#) for use in NHS Wales were implemented from January 2025. The changes apply to the assessment of licensed medicines and medicines to be used off-label. The review was in response

to the shift in the medicines access landscape and to ensure the AWMSG process meets the needs of the NHS in Wales and supports an 'All-Wales' approach to medicine access.



## AWTTC launch new webpage on medicines shortages

The webpage was launched this year and provides essential information for patients, carers, the public, and healthcare workers, on managing medicines shortages in Wales. The resources include information on serious shortage protocols and a patient information leaflet that has been developed to explain what happens if there is a shortage of a medicine in Wales.



## New version of initial clinical management of nicotine withdrawal

This guideline aims to inform and guide healthcare staff in NHS Wales about how to start nicotine replacement therapy (NRT)

to manage nicotine withdrawal in adults in secondary care. In 2024 the document was reviewed and updated to include information on the use of vapes.

Grŵp Strategaeth Meddyginiaethu Cymru Gylan  
All Wales Medicines Strategy Group

### Initial clinical management of nicotine withdrawal in adults in secondary care

November 2024

**Table 2: Guidance for prescribing additional when required NRT**

Product	Preparations	Dosing regimen	How does it work?	Benefits	Cautions	Side effects
<b>Chewing gum</b>	2 mg, 4 mg Available in a variety of fruit flavours	NRT cigarettes per day 2 mg gum when urge to smoke 4 mg gum when urge to smoke	Nicotine is absorbed through lining of mouth when gum is chewed. Nicotine is absorbed through gum and gum and dissolved.	People who smoke are concerned about gaining weight and fast craving relief instead of smoking	Nicotine can cause gastric irritation, therefore caution in people who have disease Cautions include: drinks (e.g. coffee, food) may cause decrease nicotine absorption	Irregularity Dry mouth Unpleasant taste Gastric irritation May risk in diabetes
<b>Lozenge</b>	2 mg, 4 mg Available in most flavours only	NRT cigarettes per day 2 mg lozenge when urge to smoke 4 mg lozenge when urge to smoke	Nicotine is absorbed through lining of mouth when lozenge is chewed. Nicotine is absorbed through lozenge and lozenge and dissolved.	People who smoke are concerned about gaining weight and fast craving relief instead of smoking	Nicotine can cause gastric irritation, therefore caution in people who have disease Cautions include: drinks (e.g. coffee, food) may cause decrease nicotine absorption	Irregularity Dry mouth Unpleasant taste Gastric irritation
<b>Mini Lozenge</b>	2 mg Available in most and fruit flavours, and available in most flavours only	NRT cigarettes per day 2 mg lozenge when 1-2 h when urge to smoke 4 mg lozenge when 1-2 h when urge to smoke	Nicotine is absorbed through lining of mouth or tongue	People who smoke are looking for discreet and fast craving relief	Nicotine can cause gastric irritation, therefore caution in people who have disease Cautions include: drinks (e.g. coffee, food) may cause decrease nicotine absorption	Irregularity Dry mouth

Page 12 of 18

## AWTTC nominated for Moondance Cancer Award

The One Wales Medicines process was shortlisted for a prestigious Moondance Cancer Award (the Working Together Achievement) from over 100 nominations, in recognition that AWTTC works with clinicians and patient groups to identify and assess suitable medicines for the treatment of cancer.






Another of our ambitions is to minimise medicines-related harm and improve medicines-related safety for people in Wales. Reduction

of avoidable medicines-related harm aims to minimise the risk associated with prescribing, supplying, monitoring and taking medication. When an adverse event does occur, robust systems should be in place for reporting. We have worked with AWTTTC on a range of projects that have helped to realise this ambition.


## Updated protocol for prescribing of antipsychotics for people living with dementia

The aim of this document is to guide best practice in the initiation, monitoring, review, tapering and stopping of antipsychotics for people living with dementia who express distress. In 2024, [patient information leaflets were developed and published](#) to give patients with dementia, and their families, some key questions to ask their prescriber about antipsychotic medicines.




## New sodium valproate information hub launched

As part of the collaborative effort of the Sodium Valproate Task Force established by Welsh Government, [AWTTTC launched an information hub](#) intended to focus on the risks associated with valproate use in women and girls. The hub provides links to a range of resources that have been created to help address those risks.



## New SPIRA dashboard on opioid usage published

This year a new [dashboard looking at opioid usage](#) in line with the National Prescribing Indicators has been added to the [Server for Prescribing Information Reporting and Analysis \(SPIRA\)](#) to help support health boards and NHS Trusts.






An ambition of ours is to optimise the value that NHS Wales achieves from its investments in medicines.

Given the limited resources of NHS Wales, all decisions, advice and guidance that we publish should have value considerations at their core. Welsh Government's 'A Healthier Wales' defines higher value as 'achieving better outcomes and a better experience for people at reduced cost.' We have worked with AW TTC on a variety of projects to help achieve this ambition.

## New animation for improving inhaler prescribing, use and disposal in Wales

In support of the [national inhaler decarbonisation strategy](#), AW TTC worked with Welsh Government, Public Health Wales, Asthma and Lung UK, and Cardiff Metropolitan University to produce a short [animation aimed at improving inhaler prescribing, use and disposal in Wales](#). The film is being shared widely within NHS Wales, and in primary and secondary care settings.



## Pharmacy Award presented to the Inhaler Decarbonisation Task and Finish Group

At the Welsh Pharmacy Awards [staff from AW TTC and Public Health Wales accepted the Sustainability in Healthcare award](#) on behalf of the Inhaler Decarbonisation Task and Finish Group. The Group provide coordinated support in reducing the carbon footprint associated with inhalers in line with the [national decarbonisation strategy](#).



## Good practice guide for back-up antibiotic prescribing published

New guidance has been published on the [appropriate use of back-up antibiotic prescribing](#) for specific self-limiting infections, the strategies that can be used and good practice points when implementing the strategy in primary care. A [patient information leaflet](#) was also developed to communicate key information for patients when they are given a back-up antibiotic prescription, including commonly asked questions and definitions of useful terms. It is hoped that implementation of this guide will reduce unnecessary exposure to antimicrobials.

## Position statement on prescribing of branded generics published

A [position statement](#) has been published that outlines why the prescribing of branded generics should not routinely be undertaken in NHS Wales unless there is a specific, clinical reason for doing so. The document should guide prescribers in deciding whether to prescribe by brand or branded generic.

# Medicines optimisation

## Prescribing guidance and resources

**Medicines optimisation focuses on patients and outcomes rather than processes and systems. It aims to support healthcare professionals in advising patients how to get the best outcomes from the medicines they are taking. This may involve stopping some medicines or starting others, to make sure a patient is taking the safest medicine that treats their condition. Healthcare professionals will also advise patients how to keep on taking a treatment. To help patients and prescribers get the best outcomes from medicines, we publish prescribing guidance and resources, as well as reports on prescribing performance.**

We published a range of prescribing guidance and resources between April 2024 and March 2025.

### **Prescribing dilemmas**

The AWMSG-endorsed 'Prescribing Dilemmas' document provides advice for healthcare professionals on a range of topics, including: clinical responsibility; private referrals; prescribing of medicines for an unlicensed use; and prescribing for

visitors from overseas. In November 2024, the guide was updated with an additional section on the sharing of responsibility for prescribing between a private clinician and an NHS prescriber.

### **Patient information leaflets for managing medicines shortages in Wales**

These leaflets aim to inform people about what happens if there is a shortage of a medicine in Wales. The leaflets are intended for all patients, and their families and carers. The easy-read format was developed with Learning Disability Wales, and digitally accessible and higher quality print formats are also available.



### **Common Ailments Service monograph for urinary tract infection**

The Common Ailments Service aims to improve patient access to consistent, evidence-based advice for the management of common ailments. This document includes monographs for the 27 ailments covered by the community pharmacist service. This year the formulary received a significant update with the addition of a monograph for urinary tract infection in women and transgender males who have not undergone sex reassignment surgery.

### **Patient information leaflet - Antipsychotics in patients living with dementia**

In February 2024, we published a document guiding best practice in the initiation, monitoring, review, tapering and stopping of antipsychotics when they are prescribed for people living with dementia who express distress. It also advises generalists and specialists on the management of long-term prescribing of antipsychotics where indicated. In 2024–2025 a patient information leaflet was developed to give

patients (or their carers) some key questions to ask their prescriber about antipsychotic medicines. An easy-read version was also developed with Learning Disability Wales.


## [Position statement on prescribing of branded generics in NHS Wales](#)

The prescribing of branded generics should not routinely be undertaken in NHS Wales unless there is a specific, clinical reason for doing so. This document highlights that prescribers should use their clinical judgement and consult the latest information when deciding whether to prescribe by brand or branded generic.

## [Guidance for penicillin allergy de-labelling](#)


The aim of this document is to guide best practice on the identification and removal of penicillin allergy labels in adults who have not experienced a true hypersensitivity reaction. This guidance is intended for use in patients reporting a penicillin allergy in secondary care settings in NHS Wales. A patient information leaflet with an easy-read version were developed to accompany the guidance, which included key information for patients, their families and

carers about allergy to penicillin. The easy-read format was developed with Learning Disability Wales.




## [Back-up antibiotic prescribing good practice guide](#)

The aim of this guide is to encourage more consistent implementation of a backup antibiotic prescribing strategy by all healthcare professionals in primary care. It is hoped that implementation of this guide will reduce unnecessary exposure to antimicrobials. Patient information leaflets, and an easy read version developed with Learning Disability Wales, were produced to include key information for patients when they are given a back-up antibiotic prescription.



## [Initial clinical management of nicotine withdrawal](#)





This document informs and guides healthcare staff in NHS Wales about how to start nicotine replacement therapy (NRT) to manage nicotine withdrawal in adults (secondary care). The document is intended to be used alongside the AWMMSG-endorsed [All Wales Guide: Pharmacotherapy for smoking cessation](#).



## Updates to resources

Minor updates were also made to the resources below between April 2024 and March 2025.

- [Primary Care Antimicrobial Guidelines](#)
- [All Wales Common Ailments Service Formulary](#)
- [Prescribing Dilemmas](#)
- [Pharmacotherapy for smoking cessation](#)




## Acknowledgements

Our acknowledgement process aims to highlight resources, initiatives or campaigns that are already recognised or endorsed by a national body or institute and have been implemented or accepted as good practice in Wales. Between April 2024 and March 2025, we acknowledged the following:

- [Guideline for prevention and management of tumour lysis syndrome](#)
- [Prescribing antidepressants in the perinatal period – Guidance and patient poster](#)

All of the [acknowledged resources](#) can be found on the [AWTTC website](#).



# Prescribing monitoring and analysis

## National Prescribing Indicators

We monitor and analyse prescribing data to benchmark performance and drive improvements in NHS Wales.

[National Prescribing Indicators \(NPIs\)](#) are used to highlight therapeutic priorities for NHS Wales and compare the ways in which different prescribers and organisations use particular medicines or groups of medicines. NPIs are evidence-based, clear, easily understood and allow health boards, primary care clusters, GP practices and prescribers to compare current practice against an agreed standard of quality.

### National Prescribing Indicators 2022–2025

The 14 [NPIs for 2022–2025](#), endorsed by us, focused on four priority areas (analgesics; anticoagulants in atrial fibrillation; antimicrobial stewardship; and decarbonisation of inhalers) supported by additional indicators grouped under safety and efficiency.

AWTTC publish a [quarterly report](#) analysing the performance of each health board against the current set of NPIs.

### Priority areas

Analgesics  
Antimicrobial stewardship  
Respiratory  
SGLT-2 inhibitors

### Supporting domains

Safety	Efficiency
Prescribing safety indicators	Best value biological medicines
Hypnotics and anxiolytics	Low value for prescribing
Yellow Cards	



The [Server for Prescribing Information Reporting and Analysis \(SPIRA\)](#) is updated quarterly with NPI data for health boards, clusters and individual GP practices in

Wales, giving a more detailed view of local prescribing. SPIRA also includes additional data, such as AWTTTC's inhaler decarbonisation dashboard, a range of 'Efficiencies' dashboards, and a dashboard focusing on the use of opioids across Wales. These interactive dashboards for comparative analysis of prescribing data can be accessed by users on the NHS Wales Network.

### National Prescribing Indicators 2025–2028

In December 2024, we endorsed the latest set of NPIs that will be running from [April 2025 to March 2028](#). This new set of NPIs also focuses on four priority areas: with anticoagulants in atrial fibrillation being retired, decarbonisation of inhalers being replaced by a broader set of respiratory indicators, and the addition of a set of indicators focusing on the prescribing of SGLT-2 inhibitors. For all the details about further changes that have been made, as well as supporting materials that have been developed, [please see the AWTTTC website](#).

# Medicines access

## Horizon scanning

AWTTC's horizon scanning team gathers information about medicines in development. This information supports health boards and trusts in Wales with the planning and implementation needed to make those medicines available to patients. In particular, AWTTC monitors medicines on the work programme of the National Institute for Health and Care Excellence (NICE). The team uses a secure horizon scanning repository to share horizon scanning and financial forecasting information with key people across NHS Wales.

Effective horizon scanning needs engagement and input from specialists working in the NHS in Wales. In collaboration with the Wales Cancer Network, AWTTC has established the Systemic Anti-Cancer Therapies (SACT) Horizon Scanning Collaborative Group. With input from other key partners, including the All Wales Medical Genomics Service and the National Pathology Programme, the Group reviews and assesses the potential impact of cancer medicines coming through the NICE work programme. A member of



**1 cancer medicines horizon scanning summary report**



**11 meetings with the SACT Horizon Scanning Collaborative Group**



**4 horizon scanning updates for AWMSG Steering Committee**



**We now have a very strong working relationship between the Network and AWTTC. The horizon scanning process is robust with engagement across Wales from lots of pharmacists representing different cancer sites and types, as well as representation from pathology and genomics.**

*Tracy Parry, SACT Lead Pharmacist, Betsi Cadwaladr University Health Board.*



AWTTC's horizon scanning team presented at the SACT and Acute Oncology Service Education event in Llandudno in June 2024 to highlight the work of this joint initiative.

AWTTC continues to build links with other organisations, including Advanced Therapies Wales (ATW) and the NHS Wales Joint Commissioning Committee (NWJCC). AWTTC worked alongside ATW and NWJCC to produce the first of a bi-annual [Advanced Therapy Medicinal Product \(ATMP\) Horizon Scanning Snapshot](#).

Outside Wales, the horizon scanning team is involved with a number of UK-wide horizon scanning groups, including the Medicines and Medical Devices Access Initiative. These links and collaborations, plus funding from the 2024 Voluntary Scheme for Branded Medicines Pricing, Access and Growth, will help AWTTC continue to strengthen its national horizon scanning and financial forecasting capabilities to support system preparedness across the NHS in Wales.

“  
**The collaboration on display is an example of what is possible on a Once for Wales basis, mobilising the collective insight of a diverse team. The meetings have made a clear difference to the pipeline of medicines availability in Wales, in an increasingly complex implementation landscape.**  
*Diana Matthews, SACT Lead Pharmacist & Anthony Cadogan, Deputy Director of Pharmacy, Velindre NHS Trust.*”



Welsh Government aims to make sure patients in Wales have quick and equitable access to medicines. Health technology assessment (HTA) evaluates the clinical and cost effectiveness of a medicine. NICE HTA guidance applies in England and Wales, and AWMMSG provides advice on medicines not included in the NICE work programme. AWTTTC supports AWMMSG in providing [evidence-based assessment processes](#).



[In 2024, we reviewed and refined our medicine assessment processes](#) to support an All-Wales approach to medicine access, focusing our efforts to identify areas of unmet need. Medicines are identified for assessment through the AWTTTC horizon scanning process and engagement with industry, healthcare professionals and the public.

A new group called the AWMMSG Scrutiny Panel, constituted from the NHS and with lay membership, advises on the route and priority of medicines for assessment by the AWMMSG sub-groups. AWMMSG has two sub-groups that assess medicines and give their recommendations to AWMMSG: the Licensed One Wales Medicines Assessment Group

(LOWMAG) assesses licensed medicines, and the One Wales Medicines Assessment Group (OWMAG) assesses medicines used off-label (that is, a medicine used outside the terms of its UK licence).

AWMSG plays a governance role, ensuring that the sub-groups provide a fair and transparent process. The medicine recommendations are then sent to Welsh Government for ratification. Once ratified by Welsh Government, implementing these recommendations across NHS Wales will ensure equitable and consistent access of those medicines in Wales.

Details of the new [assessment process for licensed and off-label medicines](#) are on the AWTTTC website.



## The New Treatment Fund

The New Treatment Fund (NTF), launched by Welsh Government in January 2017, aims to give patients across Wales faster access to new medicines. Health boards are expected to make medicines available for prescribing to patients within 60 days of the National Institute for Health and Care Excellence (NICE) publishing a Final Draft Guidance or Final Evaluation Determination, or within 60 days of Welsh Government's ratification of AWMMSG advice.

To monitor compliance with the NTF, AWTTTC provide regular reports to Welsh Government on the formulary status of medicines that we, or NICE, recommend for use within NHS Wales.



77

medicines on the New Treatment Fund

## Commercial Medicines Access Team

The Commercial Medicines Access Team (CMAT) is a collaborative multi-organisational team of colleagues from AWTTTC, NHS Wales Shared Services Partnership (NWSSP) and the Medicines Value Unit.


The role of CMAT is to support and monitor the implementation of AWMMSG- and NICE-recommended medicines associated with a commercial arrangement within NHS Wales. A commercial arrangement improves the cost effectiveness of a medicine; it can be a Patient Access Scheme (PAS) or a Commercial Access Agreement (CAA). This underpins the essence of [A Healthier Wales](#), allowing patients timely access to medicines, while ensuring that the NHS in Wales obtains the maximum possible value for money where medicines are concerned.

CMAT are processing an increasing number of commercial arrangements, and with an increase in the number of complex CAAs coming to Wales, the process of managing, monitoring and retrieving rebates for NHS Wales becomes significantly more



55

commercial access lines



# Implementation

challenging. To support this work, AWTTTC have set up the Commercial Arrangement Scheme Wales Group (CASWG), an AWMSG sub-committee which will increase stakeholder involvement, transparency and governance around the approval of commercial arrangements on behalf of NHS Wales.

## Blueteq High Cost Drug System



The Blueteq High Cost Drugs (HCD) System ensures that medicines are prescribed in accordance with medicines assessment guidance issued by AWMSG and NICE. Adopting the system will ensure we get the right treatment to the right people in Wales.

This year AWTTTC have appointed a Programme Manager to help support health boards and trusts with the second phase roll-out of the Blueteq HCD System in Wales. The launch of the Blueteq HCD System, starting in the second quarter of 2025, will allow NHS Wales to manage the



ever-increasing complexities associated with prescribing high-cost treatments. The Blueteq HCD System will assure health boards and trusts that the approved high-cost medicines are prescribed in line with local policy and NICE guidance, giving consistency across Wales.

# Research and publications

## Activity during 2024-2025


In addition to AWTTTC supporting all of the work that goes through AWMSG, AWTTTC's [Research Group](#) facilitates high-quality research into the safe and effective use of medicines in Wales. The key research themes include: access to medicines, medicines optimisation and medicines safety.



**7 peer-reviewed articles published**



**11 conference posters**



**6 conference talks**

### Peer-reviewed articles

- [The role of the UK National Poisons Information Service \(NPIS\) in the diagnosis of death according to neurological criteria in poisoned and non-poisoned patients](#)
- [Paediatric opioid poisoning in the UK: a retrospective analysis of clinical enquiries to the NPIS](#)
- [Patient outcome following selective serotonin reuptake inhibitor prescribing in primary care in Wales \(UK\)](#)
- [Prescribing by level of deprivation in Wales: an investigation of selected medicine groups](#)
- [Medication errors involving intravenous paracetamol in children: experience from enquiries to the NPIS](#)
- [Trends in tricyclic antidepressant prescribing and poisoning in England and Wales 2016–2020](#)
- [A case series of ibogaine toxicity reported to the UK NPIS over a 10-year period](#)

[Three posters](#) were presented at the Health Technology International (HTAi) 2024 Annual Meeting. The posters looked at the [approved use of dostarlimab for treatment of rectal cancer](#), [off-label rituximab as a first-line immunosuppressant treatment for generalised myasthenia gravis](#), and [modification of the AWMSG appraisal process for children's medicines](#).

[Four posters and three talks](#) were presented at the 44<sup>th</sup> Congress of the European Association of Poison Centres and Clinical Toxicologists (EAPCCT). Poster topics included: [recreational mushroom ingestion in adolescents](#); [a case of severe Digitalis toxicity](#); [identifying drugs with misuse potential](#); and [electronic cigarette exposures in children](#). The talks covered [intentional paracetamol ingestions in children](#), [accidental intravascular administration of wound cleaning solutions](#), and [exposures to Valerian herbal products](#).

AWTTC also presented four posters and three talks at seven conferences across the UK:

- At the [Royal College of Emergency Medicine Annual Scientific Conference](#), staff gave a talk about [sodium azide as a potential emerging public health concern](#).
- At the Health Services Research and Pharmacy Practice Conference, a talk about [the introduction of a new national tool to monitor the carbon footprint of inhalers](#) was presented.
- At the Systemic Anti-Cancer Therapies (SACT) and Acute Oncology Service (AOS) Education Event, a poster was presented about the [collaboration between AWTTC and Wales Cancer Network to develop more effective and 'Once for Wales' horizon scanning for cancer medicines](#).
- A poster about [developing easy-read formats of patient information leaflets in Wales](#) was presented at the Prescribing and Research in Medicines Management (PRIMM) 34<sup>th</sup> Annual Scientific Meeting.
- Staff presented a poster at the [British Geriatric Society Spring Meeting](#) about




the [use of data to identify potential safety risks associated with the use of monitored dosage systems](#).

- A poster was presented at the Wales Cancer Research Conference about [collecting patient outcome data across Wales for medicines accessed via the AWMSG One Wales Medicines process](#).
- At the NICE 2025 Annual Conference, the AWTTC Programme Director, Dr Andrew Champion, spoke as part of the ['Driving creative solutions in HTA'](#) session about the newly launched medicines access process in Wales. He also participated in a question-and-answer session with fellow speakers.



All Wales Therapeutics & Toxicology Centre  
Canolfan Therapiwteg a Thocsicoleg Cymru Gyfan



Grŵp Strategaeth Meddyginiaethau Cymru Gyfan  
All Wales Medicines Strategy Group

Published by:

All Wales Therapeutics and Toxicology Centre  
The Routledge Academic Centre  
University Hospital Llandough  
Vale of Glamorgan  
CF64 2XX

On behalf of the All Wales Medicines Strategy Group

All enquiries should be directed to:

Mrs Ruth Lang  
Senior Liaison Manager  
Email: [awttc@wales.nhs.uk](mailto:awttc@wales.nhs.uk)  
Telephone: 029 218 26900

Please note information in this document is correct at the time of print but may be subject to change.

For the latest information, please visit:

[awttc.nhs.wales](http://awttc.nhs.wales) (English website)

[cttcg.gig.cymru](http://cttcg.gig.cymru) (Welsh website)

[@AWTTCcomms](#) (English X account)

[@AWTTCcymraeg](#) (Welsh X account)

[LinkedIn](#) (English and Welsh)

[Return to beginning of report](#)

